We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on wallstreetbets Subreddit Page by MostCapital5741. In ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on ...

Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 ...

Hims & Hers Health (HIMS) has emerged as a disruptive force in telehealth, leveraging technology and personalization to address highly-personal health conditions while achieving scalable profitability ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims ...

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance ...